TECHNICAL PROTEINS NANOBIOTECHNOLOGY SL

Their core work

TPNBT is a Spanish biotech SME specializing in engineered recombinant proteins — particularly elastin-like recombinamers (ELRs) — for biomedical and industrial applications. They design protein-based biomaterials such as responsive hydrogels, scaffolds for tissue regeneration, and advanced drug delivery systems. Their work bridges molecular biology and materials engineering, producing programmable bio-based materials with applications in healthcare (diabetes therapy, adipose tissue regeneration) and increasingly in circular bio-economy value chains.

What they specialise in

How they've shifted over time

TPNBT's early work (2015-2019) was firmly rooted in biomedical applications — hydrogels, cell therapy, and tissue scaffolds — all using their core recombinant protein platform for healthcare purposes. Their most recent project (BioBased ValueCircle, 2020-2024) marks a deliberate pivot toward industrial bio-based materials and circular economy, training a new generation of researchers at the intersection of biotechnology and sustainable manufacturing. This evolution suggests the company is translating its deep protein engineering know-how from niche medical devices into broader industrial bio-material markets.

TPNBT is transitioning from purely biomedical applications toward industrial bio-based materials and sustainability, positioning themselves at the intersection of biotechnology and circular manufacturing.

How they like to work

TPNBT operates exclusively as a participant, never coordinating projects — typical for a specialized SME that contributes deep technical expertise without taking on consortium management overhead. With 41 unique partners across 17 countries from just 4 projects, they consistently join large, multinational consortia where they serve as a specialist technology provider. This pattern suggests they are easy to integrate into large teams and bring a well-defined contribution without competing for leadership.

Despite only 4 projects, TPNBT has built a surprisingly broad network of 41 partners across 17 countries, indicating they operate in large European consortia with strong cross-border reach. Their network spans well beyond Spain and the Iberian region.

What sets them apart

TPNBT occupies a rare niche: a private SME with deep capability in recombinant protein engineering and elastin-like recombinamers, a field typically dominated by university labs. Their ability to produce programmable bio-based materials positions them as a bridge between academic protein science and industrial applications. For consortium builders, they offer something hard to find — a commercial partner who can manufacture advanced biomaterials, not just research them.

Highlights from their portfolio

• ELASTISLET
  Largest funded project (EUR 489,000) applying their core ELR technology to a concrete medical challenge — cell therapy systems for diabetes treatment.
• BioBased ValueCircle
  Marks their strategic pivot from biomedical to industrial bio-based materials and circular economy, signaling their future direction.
• BIOGEL
  Demonstrates their foundational expertise in responsive biomimetic hydrogels, the platform technology underlying much of their work.